300 related articles for article (PubMed ID: 38372444)
1. Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.
Chen JJ; Jin ZC; Zhong BY; Fan W; Zhang WH; Luo B; Wang YQ; Teng GJ; Zhu HD
United European Gastroenterol J; 2024 Mar; 12(2):226-239. PubMed ID: 38372444
[TBL] [Abstract][Full Text] [Related]
2. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC.
Biondetti P; Saggiante L; Ierardi AM; Iavarone M; Sangiovanni A; Pesapane F; Fumarola EM; Lampertico P; Carrafiello G
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830949
[TBL] [Abstract][Full Text] [Related]
3. Role of locoregional therapies in the wake of systemic therapy.
Palmer DH; Malagari K; Kulik LM
J Hepatol; 2020 Feb; 72(2):277-287. PubMed ID: 31954492
[TBL] [Abstract][Full Text] [Related]
4. Current locoregional therapies and treatment strategies in hepatocellular carcinoma.
Cardarelli-Leite L; Hadjivassiliou A; Klass D; Chung J; Ho SGF; Lim HJ; Kim PTW; Mujoomdar A; Liu DM
Curr Oncol; 2020 Nov; 27(Suppl 3):S144-S151. PubMed ID: 33343208
[TBL] [Abstract][Full Text] [Related]
5. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
[TBL] [Abstract][Full Text] [Related]
6. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
Brandi N; Renzulli M
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239941
[TBL] [Abstract][Full Text] [Related]
7. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy.
Duan Y; Zhang H; Tan T; Ye W; Yin K; Yu Y; Kang M; Yang J; Liao R
Biosci Trends; 2024 Jan; 17(6):427-444. PubMed ID: 37981319
[TBL] [Abstract][Full Text] [Related]
8. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma.
Singh P; Toom S; Avula A; Kumar V; Rahma OE
J Hepatocell Carcinoma; 2020; 7():11-17. PubMed ID: 32104669
[TBL] [Abstract][Full Text] [Related]
9. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy.
Xue J; Ni H; Wang F; Xu K; Niu M
J Interv Med; 2021 Aug; 4(3):105-113. PubMed ID: 34805958
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.
Woeste MR; Geller AE; Martin RCG; Polk HC
Ann Surg Oncol; 2021 Mar; 28(3):1499-1510. PubMed ID: 33393028
[TBL] [Abstract][Full Text] [Related]
11. Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors.
Bertaglia V; Petrelli F; Porcu M; Saba L; Pearce J; Luciani A; Solinas C; Scartozzi M
Cytokine Growth Factor Rev; 2022 Oct; 67():1-10. PubMed ID: 35945096
[TBL] [Abstract][Full Text] [Related]
12. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
13. Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome.
Adeniji N; Arjunan V; Prabhakar V; Tulu Z; Kambham N; Ahmed A; Kwo P; Dhanasekaran R
Clin Transplant; 2020 Dec; 34(12):e14128. PubMed ID: 33098134
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
Memon K; Kulik L; Lewandowski RJ; Gupta R; Ryu RK; Miller FH; Vouche M; Atassi R; Ganger D; Mulcahy MF; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1189-1197.e2. PubMed ID: 23474327
[TBL] [Abstract][Full Text] [Related]
15. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
16. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy.
Han JW; Yoon SK
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575463
[TBL] [Abstract][Full Text] [Related]
17. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation for hepatocellular carcinoma therapy: current challenges.
Macek Jilkova Z; Ghelfi J; Decaens T
Curr Opin Oncol; 2022 Mar; 34(2):155-160. PubMed ID: 34923550
[TBL] [Abstract][Full Text] [Related]
19. Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches.
Lindemann J; Yu J; Doyle MBM
Surg Oncol Clin N Am; 2024 Jan; 33(1):143-158. PubMed ID: 37945140
[TBL] [Abstract][Full Text] [Related]
20. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.
Liu H; Wang C; Wang R; Cao H; Cao Y; Huang T; Lu Z; Xiao H; Hu M; Wang H; Zhao J
Chin J Cancer Res; 2024 Apr; 36(2):167-194. PubMed ID: 38751435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
